OSI Pharmaceuticals to Present at the Deutsche Bank Securities Annual Healthcare Conference

by C-BW@CLARI.NET (OSI PHARMACEUTICALS VIA BIZWIRE) on 2004-04-30 13:13:15

MELVILLE, N.Y.--(BUSINESS WIRE)--April 30, 2004--OSI
Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced that Robert L.
Van Nostrand, Vice President and Chief Financial Officer of OSI
Pharmaceuticals will present at the Deutsche Bank Securities Annual
Healthcare Conference on Tuesday, May 4, 2004 at 2:00PM eastern time.
Mr. Van Nostrand will provide an overview on the Company's product
portfolio and business developments.
The presentation will be webcast live and may be accessed by
visiting OSI's website at www.osip.com. A replay of the webcast will
also be available on the Company's website until Tuesday, May 18,
2004.

About OSI Pharmaceuticals

OSI Pharmaceuticals is a leading biotechnology company focused on
the discovery, development and commercialization of high-quality,
next-generation oncology products that both extend life and improve
the quality-of-life for cancer patients worldwide. OSI has a balanced
pipeline of oncology drug candidates that includes both novel
mechanism-based, gene-targeted therapies focused in the areas of
signal transduction and apoptosis and next-generation cytotoxic
chemotherapy agents. OSI's most advanced drug candidate, Tarceva(TM),
a small-molecule inhibitor of the HER1 gene, is currently in Phase III
clinical trials for lung and pancreatic cancers. OSI has a commercial
presence in the U.S. oncology market where it exclusively markets
Novantrone(R) (mitoxantrone concentrate for injection) for approved
oncology indications and Gelclair(R) for the relief of pain associated
with oral mucositis.
-=-=-
C O P Y R I G H T * R E M I N D E R

This article is Copyright 2004 by Business Wire.
All articles in the clari.* news hierarchy are Copyrighted and licensed
to ClariNet Communications Corp. for distribution. Except for articles
in the biz.clarinet newsgroups, only paid subscribers may access
these articles. Any unauthorized access, reproduction or transmission
is strictly prohibited.
We offer a reward to the person who first provides us with
information that helps stop those who distribute or receive our news
feeds without authorization. Please send reports to reward@clari.net.
[Use info@clari.net for sales or other inquiries.]

Details on the use of ClariNet material and other info can be found in
the user documentation section of .